serw-MX  [xml]  
 


    
 DeCS Categories

D02 Organic Chemicals .
D02.033 Alcohols .
D02.033.415 Fatty Alcohols .
D02.033.415.510 Hexanols .
D02.033.415.510.500 Cyclohexanols .
D02.033.415.510.500.901 Venlafaxine Hydrochloride .
D02.092 Amines .
D02.092.471 Ethylamines .
D02.092.471.683 Phenethylamines .
D02.092.471.683.948 Venlafaxine Hydrochloride .
D02.455 Hydrocarbons .
D02.455.426 Hydrocarbons, Cyclic .
D02.455.426.392 Hydrocarbons, Alicyclic .
D02.455.426.392.368 Cycloparaffins .
D02.455.426.392.368.367 Cyclohexanes .
D02.455.426.392.368.367.318 Cyclohexanols .
D02.455.426.392.368.367.318.750 Venlafaxine Hydrochloride .
D02.886 Sulfur Compounds .
D02.886.778 Thiophenes .
D02.886.778.315 Prasugrel Hydrochloride .
D03 Heterocyclic Compounds .
D03.383 Heterocyclic Compounds, 1-Ring .
D03.383.606 Piperazines .
D03.383.606.420 Prasugrel Hydrochloride .
D03.383.903 Thiophenes .
D03.383.903.315 Prasugrel Hydrochloride .
D10 Lipids .
D10.289 Fatty Alcohols .
D10.289.510 Hexanols .
D10.289.510.500 Cyclohexanols .
D10.289.510.500.901 Venlafaxine Hydrochloride .
D27 Chemical Actions and Uses .
D27.505 Pharmacologic Actions .
D27.505.696 Physiological Effects of Drugs .
D27.505.696.399 Hormones, Hormone Substitutes, and Hormone Antagonists .
D27.505.696.399.472 Hormones .
D27.505.696.399.472.161 Androgens .
G11 Musculoskeletal and Neural Physiological Phenomena .
G11.427 Musculoskeletal Physiological Phenomena .
G11.427.683 Physical Exertion .
SP5 Epidemiology and Biostatistics .
SP5.001 Epidemiology .
SP5.001.012 Epidemiologic Studies .
SP5.001.012.033 Epidemiology, Descriptive .
SP5.001.012.033.019 Temporal Distribution .
SP5.001.012.033.019.015 Period Effect .
SP5.001.012.033.024 Population Characteristics .
SP5.001.012.033.024.025 Age Effect .
SP5.001.047 Uses of Epidemiology .
SP5.001.047.138 Evaluation of the Efficacy-Effectiveness of Interventions .
SP5.001.047.158 Effectiveness .
 
 Terms
 Synonyms & Historicals
Documents
LILACS e MDL
 
Venlafaxine Hydrochloride .
1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl .
Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride .
Dobupal .
Efexor .
Effexor .
Sila-Venlafaxine .
Trevilor .
Vandral .
Venlafaxine .
Wy 45030 .
Wy-45,030 .
Wy-45030 .
Hydrochloride, Venlafaxine .
Sila Venlafaxine .
Wy 45,030 .
Wy45,030 .
Wy45030 .
A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT. .
1.00
72306
 
Physical Exertion .
Effort, Physical .
Efforts, Physical .
Exertion, Physical .
Exertions, Physical .
Physical Efforts .
Physical Exertions .
Physical Effort .
Exertion .
Effort .
Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. .
0.48
57352312
 
Age Effect .
The result of changes in the health status of individuals based on age, regardless of exposure conditions and birth cohort (age itself is a risk factor and is related to certain diseases in different conditions). .
0.48
510
 
Effectiveness .
Is a measure of the extent to which a specific intervention, procedure, regimen, or service, when deployed in the field in routine circumstaces, fulfills its objectives. .
0.46
2940
 
Evaluation of the Efficacy-Effectiveness of Interventions .
Efficacy-Effectiveness .
Procedure to systematically and objectively determine the efficiency (beneficial effect under ideal conditions) and effectiveness (beneficial effect under routine conditions) for preventive interventions. .
0.46
1400
 
Prasugrel Hydrochloride .
CS 747 .
CS-747 .
Effient .
Efient .
LY 640315 .
LY-640315 .
LY640315 .
Prasugrel .
Prasugrel HCl .
640315, LY .
747, CS .
CS747 .
HCl, Prasugrel .
Hydrochloride, Prasugrel .
A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS. .
0.46
 
Period Effect .
The result of variations in health status of individuals from the moment a factor (risk or protective) emerged. .
0.43
50
 
Androgens .
Androgen Effect .
Androgen Effects .
Androgen Receptor Agonists .
Androgenic Agents .
Androgenic Compounds .
Agents, Androgenic .
Agonists, Androgen Receptor .
Compounds, Androgenic .
Effect, Androgen .
Effects, Androgen .
Receptor Agonists, Androgen .
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. .
0.43
29622358